Recent clinical trials treating colorectal cancer with metformin as a monotherapy have had diverse outcomes [11]; however, stratification of the patient cohort based upon elevated tumour AMPK α1activity may yet reveal a place for metformin as a mono or combination therapy for future trials. Here, PRKAA2 is linked to colorectal cancer.